Morpholine → HCID 178421462, compound
Reaction equation
Cl[C:2]1[N:7]=[C:6]([NH:8][C:9]2[NH:13][N:12]=[C:11]([CH:14]3[CH2:16][CH2:15]3)[CH:10]=2)[N:5]=[C:4]([N:17]2[CH2:22][C@@H:21]3[CH2:23][C@@:18]2([CH3:25])[C:19](=[O:24])[O:20]3)[N:3]=1.[NH:26]1[CH2:31][CH2:30][O:29][CH2:28][CH2:27]1>C1COCC1>[CH:14]1([C:11]2[CH:10]=[C:9]([NH:8][C:6]3[N:7]=[C:2]([N:26]4[CH2:31][CH2:30][O:29][CH2:28][CH2:27]4)[N:3]=[C:4]([N:17]4[CH2:22][C@@H:21]5[CH2:23][C@@:18]4([CH3:25])[C:19](=[O:24])[O:20]5)[N:5]=3)[NH:13][N:12]=2)[CH2:15][CH2:16]1Participants
4
Reactant 2
Product 1
Reagents, catalysts & solvents 1
Procedure
To a solution of (1S,4S)-5-(4-chloro-6-(3-cyclopropyl-1H-pyrazol-5-ylamino)-1,3,5-triazin-2-yl)-4-methyl-2-oxa-5-azabicyclo[2.2.1]heptan-3-one (365 mg, 1.01 mmol) in THF (10 ml) was added morpholine (0.2 ml, excess). The reaction mixture was stirred at RT for 4 h and concentrated. The residue was purified by prep. HPLC to give 105B (340 mg, 66%) as a TFA salt. LC/MS [M+H]+: 513; Ret time (Method F): 2.56 min.
Workup
- concentrationconcentrated
- customThe residue was purified by prep
Sources & evidence
- ORD record
- ord-fd232cf489124f27b50de19e28c7407b
- Source dataset
- uspto-grants-2013_04
- Patent number
- US08415340B2
Reaction notes
Loading…